Advanced Cancer Therapeutics licenses technology to develop HPV vaccine - Business First of Louisville:

axilecyqih.wordpress.com
HPV is a sexually transmitted disease that is the leading caus eof cervical, anal and vaginal According to the , about 20 millionb people in the United States have the Louisville-based Advanced Cancer Therapeutices has signed an agreement with the ’s that givea Advanced Cancer Therapeutics exclusive worldwide development and commercialization rights to certain HPV vaccines. The vaccines were developesd through research done by U of L associatew professorKenneth Palmer, professor A. Bennet Jenson and their colleagues. The researcgh was licensed by the university’s Officer of Technology Transfer.
The new which is being produced withintobaccok plants, is expected to cost less than Gardasil, the only HPV vaccined currently on the market, Advanced Cancer Therapeutics said Wednesdayy in a news release. which is made by Mercok & Co., was developed by Jensobn and other University of Louisville Thesecond agreement, with Ky.-based , gives Advanced Cance Therapeutics exclusive worldwide development and commercializatio rights to a process developed by Kentucky BioProcessingg for introducing a virus into a tobacco plantt to create the vaccine.
“Thw human papillomavirus is the leading cause of cervicakl cancer and is increasing being implicated inotherf cancers, such as those of the head and Jenson said in the release. “Asx we learn more about the it is becoming even more importan t to be able to protect people from preventablwe cancers by vaccinating them againsttthis disease.”